Moteur de recherche d’entreprises européennes

Financement de l’UE (19 M €) : Trials@Home : Centre d’excellence – Essais cliniques décentralisés à distance Hor 14/08/2019 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Trials@Home : Centre d’excellence – Essais cliniques décentralisés à distance

Clinical trials increase in size, complexity and costs. This is fuelled with the need to demonstrate effects in more complex therapeutic areas, and to detect subgroups with different benefit and safety responses. Complexities, rigid clinical control, physical distance and (perceived) burden put patient engagement under pressure. (S)low recruitment and retention compromise efficiency, generalisability and validity of traditional, site-centred trials. Remote Decentralized Clinical Trials (RDCTs) and hybrid approaches address these challenges. RDCTs are an operational strategy for technology-enhanced clinical trials, which enable (semi-)continuous data collection and real-world evidence generation, increase patient recruitment and retention and decrease patient and investigator burden and costs. Trials brought to the home of patients. Paradigmatic changes in EU clinical trial design are required to fully benefit from the digital era. Yet, the feasibility of running RDCTs needs to be rigorously demonstrated together with guidance and support measures for their execution. Trials@Home brings together a very strong consortium and will reshape clinical trial design, conduct and operations, by analysing, developing and piloting standards, recommendations and tools to define and operationalize RDCTs. Trials@Home will design and run a pan-European RDCT pilot based on: a. best practices of trials with RDCT elements, b. assessment of latest technological tools, c. the regulatory and ethical framework and potential changes required to facilitate RDCTs and d. stakeholder perspectives on the change from classical RCTs to RDCTs with strong patient involvement. The results of these assessments and the pilot will drive the formulation and dissemination of recommendations and tools for the implementation of RDCTs in Europe with the ultimate goal to improve the speed, quality and efficiency of clinical trials, and improving patients’ access to innovative treatment strategies.


Abbvie Inc. 0,00 €
Allergan Ltd. 0,00 €
Astrazeneca AB 0,00 €
Bayer AG 0,00 €
Boehringer Ingelheim Internationalgesellschaft mbH 0,00 €
Cambridge Cognition Ltd. 0,00 €
Dreem 129 948 €
Eclinicalhealth Ltd. 1 959 893 €
Ethniko Kentro Erevnas Kai Technologikis Anaptyxis 423 750 €
Federation Internationale du Diabete Region Europe Aisbl 217 754 €
FH Joanneum GmbH 795 375 €
Fortrea Belgium 0,00 €
Fundacion para El Fomento de La Investigacion Sanitaria y Biomedica de La Comunitat Valenciana 355 675 €
Iqvia RDS France 0,00 €
Janssen Pharmaceutica N.V. 0,00 €
Julius Clinical Research B.V. 6 491 792 €
Medical Research Network Ltd. 480 979 €
Medtronic International Trading Sàrl 0,00 €
Merck KGaA 0,00 €
Novartis Pharma AG 0,00 €
Novo Nordisk A/S 0,00 €
Pfizer Ltd. 0,00 €
Sanofi-Aventis Recherche & Developpement 0,00 €
Stichting Lygature 264 482 €
Stichting MLC Foundation 113 174 €
Stichting World Duchenne Organization 435 800 €
Syddansk Universitet 79 392 €
Takeda Development Centre Europe Ltd. 0,00 €
Takeda Pharmaceuticals International AG 0,00 €
Teva Pharmaceutical Industries Ltd. 0,00 €
The Chancellor, Masters and Scholars of the University of Oxford 5 164,94 €
UCB Biopharma 0,00 €
Universitair Medisch Centrum Utrecht 4 568 832 €
Universiteit Utrecht 809 333 €
University of Dundee 1 483 098 €
Vital Transformation 422 555 €

https://cordis.europa.eu/project/id/831458

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.